Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina

Table 2

Results of MGMT and Ki67 immunohistochemistry, doses, length of therapy, and clinical outcome in 6 patients with intention-to-treat with TMZ.

Patient	Tumor type	MGMT	Ki67	TMZ mg/d	Months	Outcome
JB	PRL Ca	(−)	10%	140	1	Death
SA	CNFPA	ND	2%	150	1	Failure
LC	GH-oma	(−)	3%	320	4	Failure
DDO	Nelson’s	(−)	1%	240	6	Failure
CM	CD	(−)	6%	250	13	Remission
GM	CD	(−)	4%	180	29	Remission